This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
Robust and reliable analytical test methods are essential to ensure the quality and safety of pharmaceutical drug products. This work describes a single high performance liquid chromatography (HPLC) ...
New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options BRUKINSA tablets have the same ...
TORONTO, February 05, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of ...
“Developed to meet the real-world needs of patients, the new BRUKINSA tablet formulation aims to simplify treatment, reduce pill burden, and enhance ease of administration, reflecting our continuous ...
SACRAMENTO, Calif., May 19, 2025 /PRNewswire/ -- Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results